Please ensure Javascript is enabled for purposes of website accessibility

Why CASI Pharmaceuticals Is Crashing Today

By Eric Volkman - Mar 24, 2021 at 3:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors don't like that the company is hitting up the market for more cash.

What happened

CASI Pharmaceuticals (CASI 5.43%) was down by roughly 15% in late trading on Wednesday, against the more or less flat performance of the S&P 500 index. The catalyst is the company's pricing of a relatively large and dilutive public issue of new stock.

So what

CASI announced Wednesday morning that it is issuing just under 15.9 million shares of its common stock at a price of $2.05 per share. The issue's underwriters have also collectively been granted an option to buy nearly 2.4 million additional shares.

A piggy bank wearing a stethoscope.

Image source: Getty Images.

The issue should bring in total gross proceeds of roughly $32.5 million. The company expects it to close on or around this Friday, March 26.

CASI said it will utilize the monies "for working capital and general corporate purposes." Among these potential uses are acquiring the rights to new products and general and administrative expenditures.

Product rights are important to CASI, since the core of its business strategy is to sell existing medications to the massive Chinese market.

Now what

While CASI has an intriguing and offbeat business model for a pharmaceutical company, it hasn't been successful. The company's net losses are deep, approaching nearly $17 million in the most recently reported quarter. The top line has been improving, but not enough to soothe worries about the viability of that model.

Meanwhile, the new share issue is dilutive. According to Yahoo! Finance, CASI has nearly 124 million shares outstanding; the freshly minted ones will dilute this by at least 13%.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CASI Pharmaceuticals, Inc. Stock Quote
CASI Pharmaceuticals, Inc.
$0.40 (5.43%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.